» Articles » PMID: 15146415

Expression of Toll-like Receptor 2 on CD16+ Blood Monocytes and Synovial Tissue Macrophages in Rheumatoid Arthritis

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2004 May 18
PMID 15146415
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: CD16 (IgG Fcgamma receptor type IIIA [FcgammaRIIIA])-expressing CD14+ monocytes express high levels of Toll-like receptor 2 (TLR-2) and are able to efficiently produce proinflammatory cytokines such as tumor necrosis factor alpha (TNFalpha). To understand the role of CD16 and TLR-2 in monocyte and macrophage activation in rheumatoid arthritis (RA), we investigated the expression of TLR-2 on CD16+ blood monocytes and synovial tissue macrophages and the effect of CD16 and TLR-2 activation on cytokine production.

Methods: The expression of CD14, CD16, TLR-2, and TLR-4 on blood monocytes was measured by flow cytometric analysis. CD16 and TLR-2 expression in RA synovial tissue was detected by 2-color immunofluorescence labeling. CD16+ mature monocytes were prepared by incubating blood monocytes in plastic plates for 24 hours. These adhered monocytes were stimulated with lipoteichoic acid (LTA), anti-FcgammaRIII antibody, and Hsp60 for 5 hours, and culture supernatants were measured for various cytokines by immunoassay. The activation of NF-kappaB was detected by electrophoretic mobility shift assay.

Results: The frequency of CD16+ cells in all blood monocytes was significantly increased in patients with RA compared with healthy controls. TLR-2 was expressed at higher levels on CD16+ monocytes than on CD16- monocytes, while TLR-4 was expressed similarly on both monocytes. In RA synovial tissue, CD16+/TLR-2+ cells were distributed mainly in the lining layer. TLR-2 expression on monocytes was enhanced by macrophage colony-stimulating factor (M-CSF) and interleukin-10 (IL-10), but was reduced by transforming growth factor beta1, while CD16 expression was inducible by these cytokines. Adhered monocytes ( approximately 50% CD16+) produced TNFalpha, IL-1beta, IL-6, IL-8, IL-12 p40, IL-1 receptor antagonist, and IL-10 after LTA stimulation. This cytokine response was inhibited significantly by anti-TLR-2 antibody and partly by anti-TLR-4 antibody. Anti-FcgammaRIII antibody stimulation markedly enhanced the LTA-induced TNFalpha response. Hsp60 could stimulate TNFalpha production by adhered monocytes, which was inhibited similarly by anti-TLR-2 antibody and anti-TLR-4 antibody. NF-kappaB activation in adhered monocytes was induced by LTA, but this NF-kappaB activity was not augmented by anti-FcgammaRIII antibody stimulation.

Conclusion: These results suggest that CD16+ monocytes and synovial tissue macrophages with high TLR-2 expression may be induced by M-CSF and IL-10, and their production of TNFalpha could be simulated by endogenous TLR ligands such as Hsp60 and FcgammaRIIIA ligation by small immune complexes in RA joints.

Citing Articles

Myeloid-specific deletion of autotaxin inhibits rheumatoid arthritis and osteoclastogenesis.

Heo G, Jeong S, Park S, Kim S, Lee Y, Woo S Front Immunol. 2025; 15:1481699.

PMID: 39744622 PMC: 11688342. DOI: 10.3389/fimmu.2024.1481699.


Protein Expression of TLR2, TLR4, and TLR9 on Monocytes in TB, HIV, and TB/HIV.

Tamene W, Wassie L, Marconi V, Abebe M, Kebede A, Sack U J Immunol Res. 2024; 2024:9399524.

PMID: 38660059 PMC: 11042910. DOI: 10.1155/2024/9399524.


HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases.

Ren W, Zhao L, Sun Y, Wang X, Shi X Mol Med. 2023; 29(1):117.

PMID: 37667233 PMC: 10478470. DOI: 10.1186/s10020-023-00717-3.


A novel missense compound heterozygous variant in TLR1 gene is associated with susceptibility to rheumatoid arthritis - structural perspective and functional annotations.

Pasha U, Hanif K, Nisar H, Abid R, Mirza M, Wajid B Clin Rheumatol. 2023; 42(11):3097-3111.

PMID: 37479888 DOI: 10.1007/s10067-023-06702-9.


A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-B pathway.

Yoon S, Hong H, Lim H, Choi J, Choi Y, Seo S Acta Pharm Sin B. 2023; 13(3):1093-1109.

PMID: 36970199 PMC: 10031381. DOI: 10.1016/j.apsb.2022.12.001.